
Claims


1. 2-(1-Methyl-1*H*-imidazol-2-yl)ethyl 3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-{2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]benzene-1-sulfonyl}-S-alaninate of the formula (I)



(I),

or one of the salts thereof, solvates thereof or solvates of the salts thereof.

2. 2-(1-Methyl-1*H*-imidazol-2-yl)ethyl 3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-{2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]benzene-1-sulfonyl}-S-alaninate according to claim 1 of the formula (I)



(I).

3. Salt of the compound of formula (I) according to Claim 1, characterized in that the salt is a physiologically acceptable salt of the compound of the formula (I).

4. Physiologically acceptable salt of the compound of the formula (I) according to claim 3 selected from the group consisting of

2-(1-methyl-1*H*-imidazol-2-yl)ethyl 3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-{2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]benzene-1-sulfonyl}-S-alaninate hydrochloride

and

2-(1-methyl-1*H*-imidazol-2-yl)ethyl 3-{[(5-chloro-2-thienyl)carbonyl]amino}-*N*-({2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]phenyl}sulfonyl)-S-alaninate sulfate

and

2-(1-methyl-1*H*-imidazol-2-yl)ethyl 3-{[(5-chloro-2-thienyl)carbonyl]amino}-*N*-({2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]phenyl}sulfonyl)-S-alaninate methanesulfonate

and

2-(1-methyl-1*H*-imidazol-2-yl)ethyl 3-{[(5-chloro-2-thienyl)carbonyl]amino}-*N*-({2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]phenyl}sulfonyl)-S-alaninate 4-methylbenzene-sulfonate

and

2-(1-methyl-1*H*-imidazol-2-yl)ethyl 3-{[(5-chloro-2-thienyl)carbonyl]amino}-*N*-({2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]phenyl}sulfonyl)-S-alaninate maleate

and

2-(1-methyl-1*H*-imidazol-2-yl)ethyl 3-{[(5-chloro-2-thienyl)carbonyl]amino}-*N*-({2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]phenyl}sulfonyl)-S-alaninate phosphate


and

2-(1-methyl-1*H*-imidazol-2-yl)ethyl 3-{[(5-chloro-2-thienyl)carbonyl]amino}-*N*-({2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]phenyl}sulfonyl)-S-alaninate (2R,3R)-tartrate

and


2-(1-methyl-1*H*-imidazol-2-yl)ethyl 3-{[(5-chloro-2-thienyl)carbonyl]amino}-*N*-({2-ethyl-3-[(3S)-3-hydroxy-2-oxopyrrolidin-1-yl]phenyl}sulfonyl)-S-alaninate citrate.

5. Process for preparing the compound of the formula (I) or one of the salts thereof, solvates thereof or solvates of the salts thereof according to Claim 1, characterized in that the compound of the formula



(II),

is reacted with the compound of the formula



(III),

in the presence of a dehydrating agent to give the compound of the formula (I),

and the compound of the formula (I) is optionally converted with the corresponding (i) solvents and/or (ii) bases or acids into its solvates, salts and/or solvates of the salts.

6. Compound according to any of Claims 1 to 4 for use in the treatment and/or prophylaxis of diseases.

7. Use of a compound according to any of Claims 1 to 4 in the manufacture of a medicament for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.

8. Use of a compound according to any of Claims 1 to 4 in the manufacture of a medicament for the treatment and/or prophylaxis of disseminated intravascular coagulation, and/or inflammatory disorders.

9. Medicament comprising a compound according to any of Claims 1 to 4 in combination with an inert, nontoxic, pharmaceutically suitable excipient.

10. Medicament according to Claim 9 for use in the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications such as disseminated intravascular coagulation, and/or inflammatory disorders.

11. Compound according to any of Claims 1 to 4 for use in the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications such as disseminated intravascular coagulation, and/or inflammatory disorders.